Human Trials Move Beyond Early Testing
Neuralink has already advanced into human clinical trials in the United States. The company had implanted devices in 21 patients as of early 2026 and plans to significantly increase the number of procedures by the end of the year.
Much of the public attention surrounding Neuralink has centered on its potential applications for patients with severe physical disabilities. Demonstrations released by the company have shown trial participants using neural signals to control digital interfaces, including typing and computer navigation, without physical movement.
Neuralink is also developing a project known as “Blindsight,” which the company says is designed to explore whether brain stimulation technology could potentially restore aspects of vision in certain patients.
Gulf Sovereign Funds Expand Technology Investments
Oman’s investment in Neuralink comes amid broader efforts by Gulf sovereign wealth funds to secure exposure to industries expected to play a major role in future global economies. State-backed investors across the region have expanded aggressively into sectors including artificial intelligence, semiconductors, autonomous systems, advanced healthcare technologies, and digital infrastructure.
Oman’s investment in Neuralink also supports broader national efforts to reduce long-term reliance on hydrocarbon revenues by strengthening its position in global innovation-driven industries.
Regional sovereign investors, including Saudi Arabia’s Public Investment Fund and Abu Dhabi’s Mubadala, have similarly accelerated investments into AI infrastructure and emerging technologies in recent years as Gulf economies seek to position themselves as global technology and finance hubs.
Despite rising investor interest, brain-computer interface technology remains highly experimental and faces major technological, regulatory, and ethical hurdles before wider commercialization becomes possible.
Brain implant systems require extensive medical oversight, years of testing, and approval from health regulators before they can be deployed at scale. Questions surrounding patient safety, data privacy, surgical risks, and long-term neurological effects continue to shape debate around the sector.
As research continues , advances in artificial intelligence, robotics, and neural engineering have fueled growing confidence among investors that brain-computer interface systems could eventually transform areas including healthcare, rehabilitation, communications, and human-computer interaction.
Neuralink also faces competition from several companies and research groups globally that are developing technologies aimed at restoring movement, communication, or sensory capabilities through direct neural interfaces.
Oman’s investment may represent more than a financial allocation. It signals the country’s intention to participate in sectors likely to shape future technological ecosystems as Gulf governments continue repositioning around innovation and advanced industries.
OIA’s investment in Neuralink also reinforces Elon Musk’s continued ability to attract sovereign capital into his ventures despite ongoing scrutiny surrounding several of his companies. From electric vehicles and space technology to artificial intelligence and neurotechnology, Musk-linked businesses continue to draw interest from institutional investors seeking exposure to industries viewed as strategically transformative.
